The Netherlands called China, adopting a significantly more conciliatory tone; China raised the principle of 'contractual integrity' and demanded resolution of an issue.

It is important to note that Nexperia is no ordinary enterprise—it holds a pivotal position globally in the automotive chip sector. Its packaging facility in Dongguan accounts for 70% of Nexperia’s global final-product shipments. Following China’s imposition of export controls, over 5 billion chips annually would be unable to leave the country—directly disrupting the global automotive industry. Nexperia’s automotive chips hold substantial market share in mid- and low-end vehicle models worldwide; any supply interruption could force multiple European and American auto plants to halt production due to chip shortages. Although Dongguan’s packaging plant typically operates under the radar, it serves as a critical node in the global chip supply chain. This is precisely why the Dutch government—after its overt intervention—quickly felt mounting pressure and was compelled to reassess its stance. Nexperia China responded decisively: it rapidly mapped out its domestic supply chain, engaged local raw-material suppliers and packaging-and-test service providers, retained core manufacturing processes within China, and ultimately announced independent operations—catching the Netherlands off guard. In fact, the Netherlands’ bold posture stemmed largely from sustained U.S. pressure demanding that the Netherlands restrict ASML’s exports of advanced chip-manufacturing equipment to China. This pressure has been applied repeatedly—notably in September 2023, when the Netherlands banned the sale of certain lithography machine models to China. This time, however, the Netherlands proactively contacted China to seek negotiated resolution. Beyond mounting pressure from European customers, the primary driver was the Netherlands’ heavy reliance on international trade and its vital economic ties with China: bilateral trade volume has exceeded USD 100 billion for four consecutive years, making it unlikely that the Netherlands would willingly sacrifice its own economic interests. Moreover, the Netherlands recognizes ASML’s strategic importance to both the Dutch and broader European economies and technological development. Overzealous alignment with U.S. policy risks undermining ASML’s global competitiveness. Indeed, in Q3 2024, ASML’s sales in the Chinese market reached EUR 2.79 billion—nearly half its total revenue. Should China impose commensurate countermeasures, the consequences for the Netherlands would be unimaginable. Following the Dutch intervention in Nexperia, China implemented targeted countermeasures—including export controls—to exert tangible economic pressure on the Netherlands, precisely striking at its core economic concerns. In diplomatic communications, China consistently emphasized the principles of 'contractual integrity' and 'market-oriented, rule-of-law-based governance', thereby occupying the moral high ground in upholding international economic and trade rules. This principled stance has not only earned understanding from the international community but also rendered the Netherlands’ actions legally and commercially indefensible.

[Year-End Review] Essential Gene Testing Panel for Gastric Cancer and Comprehensive List of Targeted Therapies (Approved + Clinical Trials)

• Clinical significance: Rare (<1%), yet highly targetable. • Recommended therapies: Larotrectinib, Entrectinib. 5. RET fusion • Clinical significance: Rare (<1%), yet highly targetable. • Recommended therapies: Selpercatinib, Pralsetinib, Repotrectinib. II. Biomarkers requiring immunohistochemistry (IHC) testing for targeted therapy (approved + clinical trials) • Immunohistochemistry (IHC) detects biomarkers at the protein level; it is operationally simple and relatively low-cost. (I) HER2 protein expression • Interpretation criteria: IHC 3+ or IHC 2+ (with FISH confirmation required for IHC 2+) • Recommended therapies: • 1. Antibody–drug conjugates (ADCs), e.g., approved drugs such as Datopotamab deruxtecan (DS-8201) and Disitamab vedotin (RC48); • 2. Trastuzumab plus chemotherapy ± pembrolizumab; • 3. Other HER2-targeting ADCs, bispecific antibodies, monoclonal antibodies, or small-molecule inhibitors (currently enrolling in clinical trials). (II) Claudin18.2 (CLDN18.2) protein expression • Interpretation criteria: CLDN18.2 high expression is defined as ≥75% of tumor cells showing membranous staining of intensity IHC 2+ or 3+. Studies indicate an overall CLDN18.2 high-expression rate of 38.4% in gastric cancer. • Recommended therapies: • 1. Zolbetuximab: currently the only approved monoclonal antibody targeting CLDN18.2, indicated in combination with chemotherapy for first-line treatment of CLDN18.2-positive gastric cancer. • 2. Other CLDN18.2-targeting agents (clinical trials): No CLDN18.2-directed ADC has yet received regulatory approval, but several candidates have entered late-stage clinical development, including ATG-022 (Antengene), IBI343 (Innovent Biologics), SHR-A1904 (Hengrui Medicine), XNW27011 (Xynomic Pharmaceuticals), LM-302 (Lisong Bio), CMG-901 (Lepu Biopharma/Concord Medical), and JS107 (Junshi Biosciences). Detailed efficacy data are presented in the table below.

Vianode Seeks Partnership or Sale Candidates

Sep 29, 2026

Norwegian synthetic graphite producer Vianode has hired J.P. Morgan to find partners or buyers for its expansion phase, aiming to reduce Western reliance on Chinese battery materials. The company seeks capital for its Ontario plant scheduled to start production in 2029.

reuters

2026-09-29

Vianode Seeks Partnership or Sale Candidates

Vianode Seeks Partnership or Sale Candidates

FAQ